RESOLVED, that IPO supports the complete and immediate implementation of the Supreme Court of Canada’s decision in AstraZeneca Canada, Inc. v. Apotex, Inc., including abolition of Canada’s promise doctrine, to restore greater certainty and predictability with respect to patentability requirements for Canadian patent applications.